Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT03059641
What this trial is testing

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Who this might be right for
Lung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more
Geneplus-Beijing Co. Ltd. 300
Testing effectiveness (Phase 2)Looking for participantsNCT06760819
What this trial is testing

Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Solid TumorsHER2 Mutation
Bayer 111
Testing effectiveness (Phase 2)Looking for participantsNCT06071013
What this trial is testing

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Resistant Mutation
China Medical University Hospital 20
Large-scale testing (Phase 3)UnknownNCT02886195
What this trial is testing

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Who this might be right for
EGFR Gene Mutation
Fujian Cancer Hospital 120
Not applicableStudy completedNCT02777567
What this trial is testing

KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 315
Not applicableStudy completedNCT03562819
What this trial is testing

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
AstraZeneca 268
Testing effectiveness (Phase 2)UnknownNCT02066038
What this trial is testing

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Lung, Carcinoma
Sun Yat-sen University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06194448
What this trial is testing

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Who this might be right for
Lung Cancer
AstraZeneca 76
Testing effectiveness (Phase 2)Looking for participantsNCT05967689
What this trial is testing

Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Who this might be right for
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc. 220
Early research (Phase 1)UnknownNCT05504213
What this trial is testing

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 224
Testing effectiveness (Phase 2)Study completedNCT02769286
What this trial is testing

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA

Who this might be right for
Lung NeoplasmsEGFR Gene Mutations
Chonnam National University Hospital 38
Early research (Phase 1)Looking for participantsNCT07462377
What this trial is testing

EPI-326 in EGFR-mutant NSCLC and HNSCC

Who this might be right for
Epidermal Growth FactorEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Gene Mutation+12 more
EpiBiologics 110
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Large-scale testing (Phase 3)UnknownNCT03074864
What this trial is testing

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Who this might be right for
Non-small Cell Lung CancerEpidermal Growth Factor Receptor
Guangdong Provincial People's Hospital 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05132985
What this trial is testing

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Who this might be right for
NSCLCEGF-R Positive Non-Small Cell Lung Cancer
Liaoning Cancer Hospital & Institute 45
Testing effectiveness (Phase 2)Ended earlyNCT04908956
What this trial is testing

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
ETOP IBCSG Partners Foundation 6
Not applicableStudy completedNCT04795245
What this trial is testing

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 805
Early research (Phase 1)Study completedNCT03685331
What this trial is testing

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast Cancer+2 more
Abramson Cancer Center at Penn Medicine 9
Not applicableLooking for participantsNCT06304441
What this trial is testing

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 100
Next Page